GSK's Avodart To Get Panel Review For Prostate Cancer Prevention, With Merck's Proscar Along For The Ride
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Oncology Drugs Advisory Committee will review Merck's Proscar (finasteride) as well as GlaxoSmithKline's Avodart (dutasteride), even though Merck has not filed an sNDA.
You may also be interested in...
Prostate Cancer Risk Reduction sNDAs Go Before ODAC, Pitting Statistical Versus Clinical Significance
GlaxoSmithKline's Avodart and Merck's Proscar reduce the risk of low-grade prostate cancers in trials, but FDA's Oncologic Drugs Advisory Committee will hear the agency argue on Dec. 1 that the actual benefit of this is questionable.
Prostate Cancer Risk Reduction sNDAs Go Before ODAC, Pitting Statistical Versus Clinical Significance
GlaxoSmithKline's Avodart and Merck's Proscar reduce the risk of low-grade prostate cancers in trials, but FDA's Oncologic Drugs Advisory Committee will hear the agency argue on Dec. 1 that the actual benefit of this is questionable.
Reeling From Ferrlecit Loss, Watson Revamps Branded Sales Strategy
Insurance coverage was an "obstacle to launch," for Rapaflo and Gelnique, but the outlook is much better for 2010, says Watson.